The HPAPI momentum: growth, complexity and the outsourcing imperative 
Highly potent active pharmaceutical ingredients (HPAPIs) are no longer a niche. They are at the center of modern pharmaceutical innovation. As oncology, targeted therapies, and precision medicines continue to reshape global pipelines, the demand for high-potency compounds is accelerating at a sustained pace. 

Independent market analyses consistently describe a robust and expanding HPAPI market, valued in the upper tens of billions of dollars and projected to grow steadily into the early 2030s. Within this scenario, the HPAPI CDMO segment is outpacing the broader API outsourcing market. The reason is clear: the technical, safety, and regulatory complexity of handling ultra-potent compounds has raised the threshold for in-house manufacturing. 

Oncology dominates HPAPI utilization, accounting for roughly two-thirds to three-quarters of applications. The continued rise of antibody-drug conjugates (ADCs), small-molecule warheads, steroidal hormones, and other selective compounds requiring occupational exposure limits (OELs) below 10 µg/m³ — and in some cases down to the nanogram range — is reshaping expectations around containment, engineering controls, and process integration. 

In this environment, clients are not simply looking for capacity. They are seeking partners with measurable high-containment performance, scalable infrastructure, regulatory credibility, and the ability to integrate complex chemistries under one roof.  

This is precisely the space where Indena has built its distinctive CDMO proposition. 

Indena: a century of API expertise, reimagined for high potency 
Founded in 1921, Indena has long been recognized for its expertise in active ingredients derived from medicinal plants for the pharmaceutical, nutraceutical, and cosmetic industries. Over the decades, this heritage has evolved into a broader and highly specialized competence in the development and manufacturing of complex molecules–including highly potent APIs and ADC payloads. 

Today, Indena operates multiple GMP-certified sites in Italy and France, with its principal CDMO hub located in Settala, near Milan. The Italian facilities operate under EU GMP with AIFA approval, supported by system certifications such as ISO 14001 and ISO 45001, and a regulatory team experienced in interactions with global authorities including FDA, EMA and AIFA. 

What distinguishes Indena is not only regulatory compliance, but the integration of R&D and GMP manufacturing in high-containment environments—a combination that allows seamless progression from early development through clinical supply and into commercial production. 

High containment by design: from kilolab to commercial scale 
At the heart of Indena’s CDMO platform is its high-containment capability, engineered to handle products with OELs down to 1 ng/m³. This level of containment supports the safe development and manufacturing of ultra-potent small molecules and ADC payloads, where operator protection and cross-contamination control are paramount. 

The company’s infrastructure includes: 

• a dedicated HPAPI kilolab; 

• an expanded GMP synthetic plant capable of handling OEB5 compounds; 

• high-containment isolation technologies, including contained centrifugation and advanced filter dryers; 

• preparative chromatography at large scale; 

• particle-engineering technologies such as PSD spray drying from organic solvents; and 

• fully contained freeze-drying systems integrated within glove boxes. 

Recent investments (2024–2025) have further strengthened the platform. These include the installation of a state-of-the-art contained filter dryer for highly potent molecules, increased reactor capacity up to 1,000 L with plans for 3,000-L enamel reactors, and hydrogenation capability (Biazzi technology up to 10 bar). 

These upgrades extend end-to-end containment through isolation and drying, which are traditionally among the highest-risk process steps. This minimizes operator exposure and prevents cross-contamination. 

The result is not just compliance, but engineered confidence across the full development lifecycle. 

Comprehensive chemistry expertise and advanced containment capabilities 
One of Indena’s most distinctive strengths lies in its ability to combine diverse technological platforms within a unified high-containment framework. 

The company integrates: 

• modern synthetic organic chemistry; 

• semi-synthetic approaches; 

• fermentation capabilities up to 20,000-L scale, including for toxic compounds; 

• botanical extraction and complex natural product handling; and 

• high-containment downstream processing. 

This breadth is particularly relevant for oncology programs and ADC payload development, where molecules often originate from complex natural scaffolds or require fermentation-based intermediates. By combining route scouting, process development, scale-up, and high-containment manufacturing within a single coordinated environment, Indena can significantly streamline technology transfer and reduce development timelines. 

The company currently reports manufacturing 10 commercial and 13 clinical-phase HPAPIs, reflecting sustained demand across oncology and other specialty areas. This track record demonstrates not only technical capability, but operational reliability at different stages of the product lifecycle. 

Oncology and Antibody–Drug Conjugates: building a strategic platform for the future 
The increasing number of oncology New Chemical Entities (NCEs), along with the rapid expansion of ADC pipelines, is reshaping CDMO requirements. ADCs in particular require precise coordination between toxin payload production, linker chemistry, and strict containment controls. 

Indena has strategically positioned itself to support this field through advanced payload manufacturing down to 1 ng/m³ OEL, backward integration into microbial fermentation for toxin production, high-containment downstream processing, integrated freeze-drying and spray-drying technologies within glove boxes. 

Backward integration in fermentation enhances supply-chain independence and reliability for critical ADC components, an increasingly important consideration in client decision-making. By controlling both upstream and downstream phases under high-containment conditions, Indena mitigates the risk of supply interruptions and quality variability. 

The integration of fully contained freeze-drying and spray-drying technologies further elevates the HPAPI platform, combining advanced particle engineering with maximum containment. This is particularly important in ADC payload development, where powder handling, drying, and micronization can present significant exposure risks. 

As oncology pipelines continue to evolve toward higher potency and more complex modalities, this combination of chemistry, fermentation, containment engineering, and scale-up flexibility becomes a decisive advantage. 

Addressing customers’ requirements: Indena’s integrated approach 
When selecting an HPAPI CDMO, pharmaceutical and biotech companies consistently prioritize several key criteria: 

1. demonstrated containment performance at target OEL/OEB levels; 

2. end-to-end technical depth, from route scouting and scale-up to commercial supply; 

3. advanced unit operations in high containment (centrifugation, filter drying, spray drying from organic solvents, preparative chromatography, fermentation/biotransformations where required); 

4. regulatory and quality credibility; 

5. supply chain resilience and sustainability; and 

6. ADC readiness. 

Indena’s platform has been deliberately engineered around these expectations. 

Containment down to 1 ng/m³ OEL demonstrates measurable OEB4/5 performance. Integrated R&D and GMP operations at Settala enable smooth transitions from early development to commercial production. Western European manufacturing mitigates geopolitical risks and supports regulatory alignment. System certifications and environmental and occupational safety programs reinforce credibility and long-term sustainability. 

At the same time, the company maintains the flexibility that small and mid-size pharmaceutical and biotech companies often require. Customized solutions, including dedicated equipment and multipurpose pilot and industrial plants, allow sponsors to tailor development pathways without compromising containment or compliance. 

A strategic partner for complex development pathways 
In today’s HPAPI landscape, technical excellence alone is not sufficient. Customers must navigate increasingly complex development pathways, compressed timelines, and heightened regulatory scrutiny. 

Indena addresses these challenges through early-stage R&D expertise integrated with scalable GMP production, strong analytical support, continuous infrastructure investments, fermentation and synthetic chemistry under a unified quality system, the ability to progress projects from clinical phases to commercial supply within a single, specialized site. 

This integrated model reduces handoffs, simplifies technology transfer, and strengthens knowledge continuity. These are factors that directly impact time-to-market and project risk. 

A trusted choice for the high-potency era 
As HPAPI pipelines tilt toward ever-higher potency, narrower therapeutic windows, and hybrid modalities such as ADCs, outsourcing strategies are becoming more selective. Clients are concentrating work with CDMOs that can demonstrate scalable containment, proven OEB4/5 performance, and credible regulatory systems. 

Market signals consistently point to sustained growth in HPAPI outsourcing, driven by oncology and targeted therapies. In this expanding but demanding environment, Indena offers a distinctive combination: 

• ultra-low OEL handling down to approximately 1 ng/m³; 

• recent GMP capacity additions for potent isolation, drying, and advanced synthesis; 

• multi-route chemistry spanning natural, fermentation, semi-synthetic, and synthetic approaches; 

• ADC payload and linker readiness supported by backward integration; and 

• a Western European manufacturing base with robust regulatory standing. 

For pharmaceutical and biotech companies seeking a high-containment CDMO partner capable of combining chemistry breadth with containment finesse, Indena represents more than a service provider. It is a strategic collaborator equipped to translate scientific complexity into reliable, scalable manufacturing solutions. 

In the high-potency era, confidence is grounded in engineering discipline, scientific rigor, and operational excellence. At Indena, these principles guide every stage of development and every molecule we produce.